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ABSTRACT
Objective: Adenocarcinoma (AC) of the lung is now the most common histologic type of non-small cell lung cancer (NSCLC) worldwide since the past 
20 years. This study was conducted to investigate survival difference among smoker and non-smoker lung AC patients.
Methods: A retrospective observational study was conducted for 81 advanced NSCLC adult Malaysian patients in Radiotherapy and Oncology Clinic 
at Hospital Kuala Lumpur, Malaysia. A total of adult 30 Malaysian smokers and 51 non-smokers with lung AC were included. Ex-smokers were not 
included in the study. Demographic and clinical data were collected and described. For survival analysis, Kaplan–Meier test and log-rank test were 
used to calculate overall survival (OS) and analyse the difference in the survival curve. Cox proportional hazard model was used to identify prognostic 
significance of smoking status.
Results: Non-smokers showed a significant association with female gender and Stage IV NSCLC. The median OS was higher for non-smokers (493 days) 
as compared to smokers (230 days). The Cox proportional hazard model showed higher hazard ratio for smokers.
Conclusion: Non-smoking is an independent positive prognostic factor in lung AC.
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INTRODUCTION
Lung cancer is becoming one of the leading causes of cancer-related 
mortality worldwide [1]. The vast majority of lung cancer cases 
are attributed to smoking [2]. The smoking epidemic has been 
steadily decreased in developed countries whereas augmenting in 
underdeveloped and non-developed countries [3]. Non-small cell lung 
cancer (NSCLC) accounted for almost 80% of all lung cancer cases, 
comprising several histological types, including adenocarcinoma (AC), 
squamous cell carcinoma (SCC), and large cell carcinoma (LCC) [4]. 
Over the past 20 years, AC lung cancer had dramatically replaced SCC 
as the most frequent histologic type of 20% of lung cancer cases to 
approximately 40% [5]. The possible factor among smokers being the 
most frequent histologic type NSCLC included changes in the smoking 
trend from high-tar to low-tar filtered cigarettes [6]. Low-tar filtered 
cigarette result in deep and intense inhalation of tobacco smoke 
leading to greater delivery of carcinogens such as nitrogen oxide and 
nitro salted compounds to the lung periphery [7]. Passive smoking 
contributed to the shift in the cell type of NSCLC among non-smokers as 
a result of rapid inhalation of gaseous components of cigarette smoke 
into the deeper parts of the lungs as compared to the mainstream 
smoke containing more particulates [8].
This study was conducted to glance for the survival differences 
among smokers and non-smokers in lung AC. Since the mechanism of 
carcinogenesis of AC arising in smokers and non-smokers is distinct, 
it would imply differences in demographic and clinical characteristics 
and hence survival.
METHODS
This was a retrospective review of patients with NSCLC diagnosed at 
Radiotherapy and Oncology Clinic, Hospital Kuala Lumpur, Malaysia, 
from January 2009 to December 2012. The study was approved for 
research ethics by Medical Research and Ethics Committee, Ministry of 
Health, Malaysia. Patients’ ≥18 years old histopathologically confirmed 
to have locally advanced or metastatic AC were included in the 
analysis. Retrospectively collected demographic and clinical variables 
included gender, age (at diagnosis), stage of NSCLC, and smoking 
status. Data regarding smoking status included current smokers and 
non-smokers whereas ex-smokers were not included in the study. For 
survival analysis, each patient’s time began on the date of diagnosis 
of disease and ended on the date of last follow-up for living patients 
and date of death for dead patients. Survival time was calculated in 
days. Furthermore, cancer-specific mortality was documented. Deaths 
resulting from any non-cancer causes were excluded from the study.
Statistical analysis was performed using SPSS 21.0 version. Demographic 
and clinical data were analysed descriptively by dividing the study 
population into two cohorts; smokers and non-smokers. Pearson χ2 
tests were used to compare demographic and clinical variables among 
groups based on smoking status. The primary end point of this study 
was overall survival (OS). Survival was calculated using Kaplan–Meier 
test and compared using log-rank test. Prognostic importance of 
smoking status in lung AC was analysed using Cox proportional hazard 
model. A two-sided p<0.001, p<0.05 were considered statistically 
significant.
RESULTS
Characteristics of study Malaysian population categorised as smokers 
and non-smokers are listed in Table 1. There were 30 smokers and 51 
non-smokers out of total 81 NSCLC AC patients (37.0% and 63.0%, 
respectively). There were more male smokers (32.0%) than male 
non-smokers (18.5%). Most patients in both groups were between 
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41 and 64 years old (29.6% smokers vs. 47.0% non-smokers) and 
having Stage IV NSCLC (21.0% smoker vs. 53.0% non-smokers). There 
were statistically significantly higher percentages of female (p<0.001) 
and Stage IV NSCLC (p=0.022) patients in the non-smokers category. 
Median OS was 230 days for smokers and 493 days for non-smokers 
(p=0.039) (Table 2). Kaplan–Meier survival curve for smokers versus 
non-smokers is shown in Fig. 1. The hazard ratio (HR) for smokers was 
1.865 times higher as compared to non-smokers (p=0.042) (Table 3).
DISCUSSION
It is presumed that carcinogenic and mutagenic chemicals in the 
cigarette smoke induce lung carcinogenesis in smokers. However, 
non-smokers dictate distinct natural history and mechanism of 
carcinogenesis. The analysis was performed to determine disparities 
in patient characteristics and their survival among smokers and non-
smokers with lung AC.
The results of this study showed that females having lung AC were 
more likely to be non-smokers as compared to males. A similar result 
was also reported by a West Japan Oncology Group study that lung AC 
patients were mostly to be female non-smokers [9]. The statistically 
higher percentage of Stage IV NSCLC in non-smokers might be because 
this study comprised a higher proportion of Stage IV (74.0%) and non-
smoker (63.0%) AC patients. OS was longer, and HR to death was less 
for non-smokers as compared to smokers. Similarly, a prospective study 
reported that non-smoker lung AC patients had improved OS and non-
smoking showed positive prognostic significance in lung AC [10].
CONCLUSION
In conclusion, this study demonstrated that smoking status has a 
prognostic impact in patients with lung AC.
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Table 1: Demographic and medical variables of patients
Characteristics Smoker’s n (%) Non-smoker’s n (%)
Total patients (n=81) 30 (37.0) 51 (63.0)
Gender
Male 26 (32.0) 15 (18.5)
Female 4 (5.0) 36 (44.4 )
Age (years old)
18-40 2 (2.4) 5 (6.1)
41-64 24 (29.6) 38 (47.0)
≥65 4 (5.0) 8 (10.0)
NSCLC stage
III A 4 (5.0) 2 (2.4)
III B 9 (11.1) 6 (7.4)
IV 17 (21.0) 43 (53.0)
NSCLC: Non-small cell lung cancer
Table 2: Overall survival of smokers versus non-smokers
Smoking status Median OS (days) 95% CI p
Smoker 230 115.092-344.908 0.039*
Non-smoker 493 262.284-723.716
OS: Overall survival, CI: Confidence interval, *p<0.05
Table 3: Survival analysis by Cox proportional hazard model
Parameter HR (95% CI) p
Male versus female gender 0.914 (0.509-1.643) 0.764
Smoker versus non-smoker 1.865 (1.022-3.406) 0.042*
Increasing age 0.836 (0.433-1.614) 0.593
HR: Hazard ratio, CI: Confidence interval, *p<0.05
Fig. 1: Kaplan–Meier overall survival curve for smoker versus 
non-smoker
